Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.